INFU
InfuSystem Holdings, Inc.
INFU's fundamentals are strong: it turned 17% of its revenue into free cash flow and earnings per share grew 63%. At 34x earnings, it's trading below its usual 50x. Analysts expect strong earnings growth.
INFU Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
INFU's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
INFU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $14.79 | — |
| Cheap | 28x | $12.19 | -18% |
| Current | 34x | $14.79 | — |
| Fair | 50x | $21.97 | +49% |
| Expensive | 333x | $146 | +890% |
Historical ranges are pointers, not guarantees.
INFU's PE is in its cheap range at 34x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
INFU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect INFU's earnings to grow and its profitability to improve, with its revenue holding steady.
INFU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.59 | +34% |
| Q3 2026 | $0.44 | +63% |
| Q2 2026 | $0.40 | +67% |
| Q1 2026 | $0.37 | +147% |
| Q4 2025 | $0.31 | +182% |
| Q3 2025 | $0.27 | +286% |
| Q2 2025 | $0.24 | +1100% |
| Q1 2025 | $0.15 | +1400% |
| Q4 2024 | $0.11 | +175% |
INFU's earnings per share have fallen from their peak: $0.44 over the past year, against $0.85 in early 2021.
INFU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.6M | +3% |
| Q2 2026 | $36.9M | +2.6% |
| Q1 2026 | $33.7M | -3% |
| Q4 2025 | $36.2M | +7% |
| Q3 2025 | $36.5M | +3.3% |
| Q2 2025 | $36M | +6.8% |
| Q1 2025 | $34.7M | +8.5% |
| Q4 2024 | $33.8M | +6.5% |
INFU's revenue grew through 2024 and has held roughly level since: $38M last quarter, up 3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +2.2 points |
| Q2 2026 | 11% | +0.8 points |
| Q1 2026 | 4.7% | +2.9 points |
| Q4 2025 | 10% | +2.5 points |
| Q3 2025 | 10% | +1.2 points |
| Q2 2025 | 10% | +5 points |
| Q1 2025 | 1.8% | +4.4 points |
| Q4 2024 | 7.7% | +3.8 points |
INFU's operating margin was 13% last quarter, up 2.2 points from the same quarter a year ago.
INFU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $10.3M | +22% |
| Q2 2026 | $6.7M | -1.6% |
| Q1 2026 | $813K | -51% |
| Q4 2025 | $7M | -5.5% |
| Q3 2025 | $8.4M | -14% |
| Q2 2025 | $6.8M | +244% |
| Q1 2025 | $1.6M | +746% |
| Q4 2024 | $7.4M | +74% |
INFU generated $25M in free cash flow over the past year, up 2.1% from the year before.
INFU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +152K shares |
| 1 year | +0.6% | +126K shares |
| 3 years | -3% | -647K shares |
| 5 years | +2.4% | +494K shares |
| Available history | +1.1% | +233K shares |
INFU has 21M diluted shares, up 0.6% from a year ago, despite $6M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $605,000 |
| Q2 2026 | $3.5M |
| Q1 2026 | $809,000 |
| Q4 2025 | $1.3M |
| Q3 2025 | $2.2M |
| Q2 2025 | $3.5M |
| Q1 2025 | $2.9M |
| Q4 2024 | $199,000 |
INFU spent $6M buying back its own shares over the past year, down 28% from the year before.
INFU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.7x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.2x | Healthy |
INFU's net debt is less than a year of its operating earnings (EBITDA).
INFU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 84.8 | Overbought |
INFU's weekly RSI is 73 (overbought) and its Stochastic is 85 (overbought).
INFU PE vs Healthcare Sector
| Metric | INFU | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 30% above |
| PE % | 31 | 29 | 2 pts above |
INFU is trading at 34x earnings, a 30% premium to the Healthcare sector's median of 26x.
INFU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.7 | 8.3% above |
| 20 week MA | $12.1 | 22% above |
| 50 week MA | $10.3 | 44% above |
| 100 week MA | $8.93 | 66% above |
| 200 week MA | $8.82 | 68% above |
INFU is in an uptrend: it's above all five of its weekly moving averages, and 68% above its 200-week average.
INFU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.22 | $19.0 | +131% |
| 2021 | $19.0 | $16.9 | -11% |
| 2022 | $16.9 | $8.50 | -50% |
| 2023 | $8.50 | $10.5 | +24% |
| 2024 | $10.5 | $8.14 | -23% |
| 2025 | $8.14 | $8.96 | +10% |
| 2026 YTD | $8.96 | $14.8 | +65% |
INFU's yearly returns have swung widely, from +131% in 2020 to −50% in 2022. It's up 65% so far in 2026.